Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication "SAFARI"

Completed

Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- Female and male subjects ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation
- Who are treated with Vitamin K antagonists (VKA) with issues for at least the 4 previous weeks (issues are assessed on medical judgment)
- Who start treatment with rivaroxaban to prevent stroke or non-CNS (central nervous system) systemic embolism
- With anticoagulation therapy planned for at least 6 months

Exclusion Criteria

- Contra indication to the use of Xarelto as described in the Summary of Product Characteristics (SmPC); key contra indications are:
- Hypersensitivity to the active substance or to any of the excipients listed in SmPC section 6.1.
- Lesion or condition at significant risk of major bleeding
- Concomitant treatment with any other anticoagulant agent
- Clinically significant active bleeding
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C
- Pregnancy and breast feeding